Dr. Reddy’s Labs - Expert Committee Suggestions Aides Business Visibility For Sputnik: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
The government’s Subject Expert Committee of the Central Drugs Standard Control Organization has recently recommended Russian Direct Investment Fund’s Sputnik V Covid-19 vaccine for Emergency Use Authorization in India.
Dr. Reddy’s Laboratories Ltd. has exclusive marketing and distribution rights for the first 250 million doses of Sputnik V vaccines in India.
Considering the base case scenario of a pricing cap of $2 per dose for the vaccine, we believe the upside potential for revenues is ~$300 million for the company for the duration of the contract.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.